About MICROBIOTIX, INC.
Microbiotix, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of proprietary small molecule drugs that target serious infectious diseases, including multi-drug resistant pathogens. The company has consistently been the top recipient of NIH awards amongst Massachusetts biotech/pharma companies.
Discovery and development of proprietary small molecule drugsTargeting serious infectious diseases and multi-drug resistant pathogensDevelopment of nucleoside analog dual DNA polymerase/kinase inhibitors
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| TO DEVELOP THE PPZ SERIES OF SMALL MOLECULE PAN-FILOVIRUS ENTRY INHIBITORS THROUGH LEAD OPTIMIZATION, SELECTIO | Department of Health and Human Services | $5.0M | |
| Federal contract award | Department of Defense | $2.6M | |
| TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOS | Department of Health and Human Services | $7.3M |
Teaming History
Prime contractors MICROBIOTIX, INC. has worked under:
- Trustees Of Boston University — 6 subcontract(s)
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to MICROBIOTIX, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.